Lead Product(s): Efruxifermin
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AKR-001
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2021
Efruxifermin (EFX) is an Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body.
Lead Product(s): Tvb-2640
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ASC40
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Ascletis Pharma
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Financing February 11, 2021
Funds raised will support the advancement of TVB-2640, an oral, first-in-class fatty acid synthase (FASN) inhibitor, including a planned Phase 2b trial evaluating the impact on histological endpoints.